MedTrace Logo

Evaluate the Efficacy and Safety of KI1107 in Patients Whose TG Level is Not Adequately Controlled With Rosuvastatin Calcium Monotherapy While LDL-C is Properly Controlled

NCT03026933 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 215

Last updated 2017-01-20

No results posted yet for this study

Summary

To examine variation rate of Non-HDL with KI1107 comparison Rosuvastatin monotherapy.

Conditions

  • Dyslipidemias

Interventions

DRUG

KI1107 4 Capsules, QD

KI1107 4 Capsules

DRUG

Rosuvastatin Calcium 20 MG, QD

Rosuvastatin Calcium 20mg, QD

Sponsors & Collaborators

  • Kuhnil Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2016-03-31
Completion
2016-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03026933 on ClinicalTrials.gov